First-in human assessment of the UroActive <sup> <i>®</i> </sup> electronic Artificial Urinary Sphincter for treating male stress urinary incontinence (SUI)
In men with SUI, the UroActive<sup>®</sup> device demonstrates promising feasibility, safety, and functional outcomes during the 365 days post-activation. Patients experienced substantial symptom improvement and high satisfaction, with no surgical revisions. Larger studies with extended follow-up are needed to confirm these findings and assess long-term device performance.
Authors
- Emmanuel Chartier‐Kastler (ORCID: https://orcid.org/0000-0003-4241-8125)
- J. Cotte
- Anne Denormandie (ORCID: https://orcid.org/0000-0001-7610-3258)
- P. Mozer
- A. Beaugerie
- M. Perrouin-Verbe
- C. Plassais (ORCID: https://orcid.org/0000-0001-8681-386X)
- S. Tran
- Dan Elliott
Institutions
- Mayo Clinic (US)
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Handicap neuromusculaire : Physiopathologie, Biothérapie et Pharmacologie appliquées (FR)
- Institut Systèmes Intelligents et de Robotique (FR)
Publication Details
- Journal
- The Journal of Urology
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1097/ju.0000000000004945
- Primary Topic
- Pelvic floor disorders treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00